Research Reviews
Ozempic or Wegovy Before Sedation or General Anesthesia: What a Gastric Ultrasound Study Found
A 2024 cross-sectional study in JAMA Surgery found increased residual gastric content on ultrasound in 56% of users of once-weekly injections acting on glucagon-like peptide-1 (GLP-1), compared with 19% of nonusers, despite recommended fasting. These are ultrasound findings, not actual pulmonary aspiration rates. The study did not establish a uniform medication interruption interval that ensures safety. Procedures planned with numbing cream or local anesthesia alone differ from its direct question; cosmetic procedures involving sedation or general anesthesia need separate consideration. Do not adjust medication yourself. Tell the prescribing and procedural clinicians in advance, and confirm Korean authorization information with the relevant regulator and clinical team.
- Increased residual gastric content was observed in 56% of users and 19% of nonusers. Actual aspiration events were not measured.
- Filler, botulinum toxin, surface laser, and “skin booster” procedures using only topical or local anesthesia differ from the study’s direct question. Sedation or general anesthesia changes the discussion.
- No uniform interruption interval ensuring safety was established. Share medication use with the prescribing and procedural teams instead of making an adjustment yourself; Korean authorization details require separate confirmation.
Researchers compared medication use with gastric ultrasound findings at one point in time in 124 people who had followed recommended fasting conditions. It cannot supply a common risk estimate for every cosmetic procedure. Sedation, which reduces awareness and responsiveness through medication, and general anesthesia need to be distinguished from topical or local anesthesia alone.[1]
Hyojung Moon, MD, was not an author of the cited study and reports no interest related to the study drugs. Medication use or interruption needs discussion with the prescribing and procedural clinicians. This research review does not determine Korean authorization details; current regulatory information and individual decisions need confirmation with the regulator and clinical team.
In their cross-sectional observational study, Sen and colleagues prospectively enrolled a convenience sample of adults awaiting elective procedures under anesthesia. All came from one U.S. tertiary, university-affiliated hospital. The study appeared in JAMA Surgery in 2024. The authors reported no conflicts of interest. One coauthor received National Institutes of Health funding; the authors said the funder did not participate in the research process or publication decision.[1]
Key findings
- The study enrolled 124 adults at one U.S. tertiary, university-affiliated hospital in 2023: 62 weekly injection users and 62 nonusers.
- Participants met the study’s fasting requirements. Ultrasound assessed solids and liquids in the stomach before anesthesia.
- Increased residual gastric content was present in 35 of 62 users (56%) and 12 of 62 nonusers (19%). These proportions do not describe pulmonary aspiration.
- After accounting for measured differences such as age, sex, body mass index, and diabetes, the adjusted prevalence ratio was 2.48. It describes an association with the ultrasound finding, not proof that the medication caused aspiration.
- Gastric ultrasound was a surrogate measure relevant to aspiration assessment. Actual aspiration events were not measured.
- An exploratory analysis truncated the variable for time since the last dose at 7 days. Small numbers for individual days prevented the study from establishing a uniform interruption interval that ensures safety.
- In cosmetic care, the actual anesthesia plan matters more than the procedure’s name. Sedation or general anesthesia calls for advance disclosure of medication use; topical or local anesthesia alone differs from this study’s direct question.
Why the anesthesia plan matters
Pulmonary aspiration means stomach contents enter the airway, an issue considered when planning sedation or general anesthesia. A filler, botulinum toxin, surface laser, or skin booster procedure performed with only numbing cream or local anesthesia and no planned sedation is a different setting. “Skin booster” is an umbrella term for various injectable products. The same procedure name can involve different anesthesia plans, so the name cannot establish whether this study applies.
The measured outcome was increased residual gastric content, not aspiration itself. A surrogate measure tracks a related condition rather than counting the event itself. An ultrasound finding may inform anesthesia planning, but finding gastric contents does not mean aspiration occurred. The meaning of 56% depends on keeping that distinction attached to the number.[1]
What the study examined
Design and participants
From June 6 to July 12, 2023, researchers enrolled adults awaiting elective procedures under anesthesia at one U.S. tertiary, university-affiliated hospital. The researchers used a convenience sample for an observational comparison at one point in time. It was not a randomized trial. Of 124 participants, 62 used a weekly GLP-1–based injection and 62 did not.[1]
Participants had fasted for at least 2 hours for clear liquids, 6 hours for a light meal, and 8 hours for a heavy meal. These were study inclusion conditions, not a personal fasting prescription.[1]
The ultrasound method was validated in people with normal gastric anatomy. The study excluded previous gastric surgery or a large hiatal hernia, pregnancy, trauma within 1 month, and inability to lie on the right side for the scan. These exclusions limit the population to which the findings apply; they are not general contraindications to the medications.[1]
The study included users of once-weekly semaglutide, dulaglutide, or tirzepatide. Its exposure definitions name the ingredients; the product names below are naming examples and do not identify which products the participants used. Ozempic and Wegovy are semaglutide product names, Trulicity is a dulaglutide product name, and Mounjaro and Zepbound are tirzepatide product names. Semaglutide and dulaglutide are GLP-1 receptor agonists; tirzepatide acts on both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. Daily liraglutide formulations, known by product names such as Saxenda and Victoza, were not studied. These findings do not apply automatically to every formulation.[1]
The ultrasound definition matters
Increased residual gastric content meant solids, thick liquids, or more than 1.5 mL/kg of clear liquid on gastric ultrasound. Reducing that definition to food remaining in the stomach would leave out part of the measured outcome.[1]
What the group difference means
The finding occurred in 35 of 62 users (56%) and 12 of 62 nonusers (19%), an unadjusted absolute difference of 37 percentage points.[1]
After adjustment for measured characteristics including age, sex, body mass index, diabetes, physical status, and time since the last intake, the prevalence ratio was 2.48 (95% confidence interval [CI] 1.23–4.97). The prevalence ratio compares how common the ultrasound finding was in each group after accounting for measured differences. Adjustment in an observational study cannot establish causation. This is not a 2.48-fold estimate of aspiration risk.[1]
What the interruption analysis could not answer
The researchers explored the relationship between days since the last injection and the ultrasound finding, truncating the time variable at 7 days. They did not identify a statistically clear association. There were too few participants at individual time points to establish an interruption interval that ensures safety. This analysis supports neither the claim that stopping the medication has no effect nor the claim that a longer interruption ensures safety.[1]
Four ways to interpret the findings
1. How perioperative guidance developed
Early perioperative guidance drew on limited case reports. In 2024, multi-society clinical practice guidance emphasized shared decisions that consider individual risk alongside blood glucose and metabolic needs, rather than uniform interruption. This study added ultrasound observations, but did not establish an interruption interval for everyone.[1–3]
The 2024 guidance also explains why stopping treatment is not a neutral step: withholding medication may create metabolic risk such as hyperglycemia. The prescribing, procedural, and anesthesia teams need to balance these concerns together.[2]
2. What the study design can establish
The researchers enrolled 124 people prospectively and used consistent ultrasound criteria to compare the groups. A convenience sample at one hospital still leaves possible selection bias and unmeasured group differences. With no direct aspiration outcome, this is observational evidence prompting safety assessment, rather than an estimate of accident frequency or proof of causation.[1]
3. Why the planned anesthesia matters
For an invasive cosmetic procedure with planned sedation or general anesthesia, the medication, last dose, recent dose escalation, and gastrointestinal symptoms belong in anesthesia planning. These symptoms include nausea, vomiting, abdominal pain, indigestion, or constipation. The findings should not become a blanket interruption or additional fasting instruction for procedures using only topical or local anesthesia without sedation.[1,2,4–6]
4. Information to share before a procedure
Confirm the anesthesia plan alongside the medications currently used. When sedation or general anesthesia is planned, advance disclosure to the prescribing and procedural clinicians allows a plan suited to the person’s circumstances. The study does not instruct an individual to stop a drug.
What to take from the study
Weekly injection users more often had increased residual gastric content after the study’s fasting conditions, but the figures are not aspiration rates and establish no uniform interruption interval ensuring safety. Distinguish topical or local anesthesia alone from planned sedation or general anesthesia. For the latter, share the medication and last dose, recent dose increases, and gastrointestinal symptoms with the team in advance. Medication changes need agreement with the prescribing clinician.
Limits to keep in view
- The sample comprised 124 adults available for enrollment at one U.S. tertiary, university-affiliated hospital.
- A cross-sectional observational design cannot establish causation between medication use and ultrasound findings.
- Background conditions and physical status differed between groups. Unmeasured differences may remain after adjustment.
- The primary outcome was a gastric ultrasound surrogate, not actual pulmonary aspiration. The original paper also notes uncertainty about the gastric volume threshold at which aspiration risk meaningfully rises.
- The interruption analysis was exploratory, with small numbers for individual days, and could not establish a uniform interruption interval ensuring safety.
- A U.S. elective-anesthesia setting cannot supply a common risk estimate for all outpatient cosmetic and skin procedures in Korea.
References
- Sen S, Potnuru PP, Hernandez N, et al. “Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia.” JAMA Surgery. 2024;159(6):660–667. DOI: 10.1001/jamasurg.2024.0111. PMID: 38446466. https://pmc.ncbi.nlm.nih.gov/articles/PMC10918573/
- Kindel TL, Wang AY, Wadhwa A, et al. “Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period.” 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11666732/
- American Society of Anesthesiologists, “American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.” June 29, 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative
- Korean Society of Anesthesiologists, “환자안전 수술 시설 인증 서비스” (in Korean). https://general.anesthesia.or.kr/contents/business.php
- Ministry of Food and Drug Safety and Korea Institute of Drug Safety & Risk Management, “GLP-1 계열 비만치료제 안전하게 사용하기” (in Korean). https://www.mfds.go.kr/brd/m_227/view.do?itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&page=3&seq=33373
- Korea Disease Control and Prevention Agency National Health Information Portal, “비만” (in Korean). https://health.kdca.go.kr/healthinfo/biz/health/gnrlzHealthInfo/gnrlzHealthInfo/gnrlzHealthInfoView.do?cntnts_sn=6694
Frequently asked questions
Does this study apply directly to filler or botulinum toxin injections?
A procedure using only numbing cream or local anesthesia, with no planned sedation, is outside the study's direct question. The actual anesthesia plan can still vary with the procedure's extent and the person's condition, so whether sedation is planned needs separate confirmation.
What about a surface laser procedure or a skin booster with numbing cream?
If only topical or local anesthesia is planned, the procedure differs from the sedation or general-anesthesia setting discussed here. That distinction is not a guarantee that everything is appropriate. The procedural clinician still needs to assess the actual anesthesia method and the person's general health.
Do 56% and the adjusted prevalence ratio of 2.48 measure aspiration risk?
No. The 56% is the proportion of users with increased residual gastric content on ultrasound. The adjusted prevalence ratio of 2.48 compares the prevalence of that finding after accounting for measured group differences. Actual aspiration events were not measured, so neither number is an aspiration rate or a multiplier of aspiration risk.
How many days should a GLP-1 injection be stopped before a procedure?
This study did not establish a uniform interruption interval that ensures safety. Do not stop or restart the medication yourself. The prescribing and procedural teams need to consider why it is used, recent dose escalation, gastrointestinal symptoms, and the planned anesthesia together.
What information should I share before the procedure?
First clarify whether sedation or general anesthesia is planned. If it is, tell the team the medication's name, when it was last taken, any recent dose increase, and symptoms such as nausea, vomiting, abdominal pain, indigestion, or constipation. This information supports a clinical discussion; it is not a checklist for deciding your own risk.